Gilles Gosselin is the CNRS Research Director who was handed over (Idenix Senior Scientist Fellow) to IDENIX Laboratories (http://www.idenix.com). Gosselin is attached to the Institut des Biomolécules Max Mousseron, UMR 5247 CNRS Universités Montpellier 1 and 2 (http://www.ibmm.univ-montp1.fr, Director: Professor Jean Martinez). Gosselin obtained the Doctorat 3ème cycle (organic chemistry), USTL, Montpellier, France, in 1975, and the Ph.D. degree (sciences), USTL, Montpellier, France, in 1982. His current research main interests are design, synthesis, and study of novel nucleoside analogues as potential antitumour and antiviral (AIDS and hepatitis) agents. Gosselin is a Coinventor of the drug Telbivudine (Tyzeka, Sebivo) marketed (http://www.novartis.com) for the treatment of chronic B hepatitis. He is also a Coinventor of a new molecule, IDX184 (http://www.idenix.com), which currently is in clinical phase II for the treatment of C hepatitis. Gosselin was a Cofounder (January, 2001), Elected Secretary (January, 2001–December, 2003; January, 2004–December, 2006), Elected Member of the Advisory Board (January, 2007–December, 2010), and Elected Vice President (January, 2011) of the International Society for Nucleosides, Nucleotides, and Nucleic Acids (http://www.is3na.org).
Biography Updated on 30 January 2012